首页 文献索引 SCI期刊 AI助手
期刊目录筛选

期刊名：Lancet diabetes & endocrinology

缩写：

ISSN：2213-8587

e-ISSN：2213-8595

IF/分区：41.8/Q1

文章目录 更多期刊信息

共收录本刊相关文章索引2699条
Clinical Trial Case Reports Meta-Analysis RCT Review Systematic Review
Classical Article Case Reports Clinical Study Clinical Trial Clinical Trial Protocol Comment Comparative Study Editorial Guideline Letter Meta-Analysis Multicenter Study Observational Study Randomized Controlled Trial Review Systematic Review
Childhood obesity: a growing pandemic [0.03%] 儿童期肥胖：一个日益严重的流行病
The Lancet Diabetes Endocrinology The Lancet Diabetes Endocrinology
Editorial The lancet. Diabetes & endocrinology. 2022 Jan;10(1):1. DOI:10.1016/S2213-8587(21)00314-4 2022
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial [0.03%] 背景疗法和治疗联合应用基础上 empagliflozin 治疗射血分数降低的心力衰竭（EMPEROR-Reduced）的探索性分析：一项随机双盲试验
Subodh Verma,Nitish K Dhingra,Javed Butler et al. Subodh Verma et al.
Background: It is important to evaluate whether a new treatment for heart failure with reduced ejection fraction (HFrEF) provides additive benefit to background foundational treatments. As such, we aimed to evaluate the e...
Comment The lancet. Diabetes & endocrinology. 2022 Jan;10(1):35-45. DOI:10.1016/S2213-8587(21)00292-8 2022
Trends in leading causes of hospitalisation of adults with diabetes in England from 2003 to 2018: an epidemiological analysis of linked primary care records [0.03%] 2003年至2018年英格兰糖尿病成人住院主要原因的变化趋势：对链接的一级护理记录进行流行病学分析
Jonathan Pearson-Stuttard,Yiling J Cheng,James Bennett et al. Jonathan Pearson-Stuttard et al.
Background: Diabetes leads to a wide range of established vascular and metabolic complications that has resulted in the implementation of diverse prevention programmes across high-income countries. Diabetes has also been ...
Comment The lancet. Diabetes & endocrinology. 2022 Jan;10(1):46-57. DOI:10.1016/S2213-8587(21)00288-6 2022
The changing character of diabetes complications [0.03%] 糖尿病并发症性质的变化
Srikanth Bellary Srikanth Bellary
The lancet. Diabetes & endocrinology. 2022 Jan;10(1):5-6. DOI:10.1016/S2213-8587(21)00313-2 2022
Is the impact of add on heart failure therapy influenced by background therapy? [0.03%] 背景治疗是否会影响添加心力衰竭治疗的疗效？
Lars Rydén,Giulia Ferrannini Lars Rydén
The lancet. Diabetes & endocrinology. 2022 Jan;10(1):3-5. DOI:10.1016/S2213-8587(21)00311-9 2022
COVID-19 and diabetes in Africa: a lethal combination [0.03%] COVID-19和非洲的糖尿病：致命组合
Talha Burki Talha Burki
The lancet. Diabetes & endocrinology. 2022 Jan;10(1):23. DOI:10.1016/S2213-8587(21)00315-6 2022
SGLT-2 inhibitors: does it matter if they prevent type 2 diabetes [0.03%] SGLT-2抑制剂：其能否预防2型糖尿病重要吗
Alice Y Y Cheng Alice Y Y Cheng
The lancet. Diabetes & endocrinology. 2022 Jan;10(1):2-3. DOI:10.1016/S2213-8587(21)00310-7 2022
Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials [0.03%] dapagliflo锌在慢性肾病或心力衰竭患者中新发2型糖尿病的合并分析：DAPA-CKD和DAPA-HF试验
Peter Rossing,Silvio E Inzucchi,Priya Vart et al. Peter Rossing et al.
Background: Chronic kidney disease and heart failure are insulin resistant states associated with a high incidence of diabetes. We assessed the effect of dapagliflozin on new-onset type 2 diabetes in a pooled analysis of ...
Comment The lancet. Diabetes & endocrinology. 2022 Jan;10(1):24-34. DOI:10.1016/S2213-8587(21)00295-3 2022
Telehealth for people with diabetes: poised for a new approach [0.03%] 糖尿病患者的远程医疗服务：新的方法即将出现
Korey K Hood,Jessie J Wong Korey K Hood
The lancet. Diabetes & endocrinology. 2022 Jan;10(1):8-10. DOI:10.1016/S2213-8587(21)00312-0 2022
Access to insulin and diabetes care in the Philippines [0.03%] 菲律宾的胰岛素获取和糖尿病护理问题
Michelle Ann B Eala,John Jefferson V Besa,Regiel Christian Q Mag-Usara et al. Michelle Ann B Eala et al.
The lancet. Diabetes & endocrinology. 2022 Jan;10(1):16. DOI:10.1016/S2213-8587(21)00309-0 2022